JOHANNESBURG — Tuberculosis, an airborne disease spread via the inhalation of droplets primarily from the coughs of infected people, is the world’s deadliest infectious disease, claiming 1.5 million lives in 2018. In South Africa, 322,000 new cases are diagnosed annually.
A specific treatment — a combination of antibiotics — can cure most patients in around six months. But multidrug-resistant TB, or MDR-TB, is not so simple to treat. This form of the disease does not respond to the two most powerful TB medicines: isoniazid and rifampin. Around 8.5% of MDR-TB cases are considered extensively drug-resistant, or XDR, which is when there is additional resistance to other TB medicines.
Unless MDR-TB is tackled, efforts to eradicate the disease as a whole are undermined, said Dr. Xavier Padanilam, chief medical officer at the Sizwe Tropical Diseases Hospital in Johannesburg.
Fortunately, things are starting to change in South Africa and around the world, thanks to the development of new tools — including new medicines and better diagnostics — to tackle MDR-TB.
Access this visual story: Join Devex on the ground in Johannesburg as we explore how South Africa is spearheading efforts to tackle MDR-TB.
About the author
Devex Editor
Thanks for reading and for your interest in Devex. Sponsored content is produced in collaboration between Devex’s partnerships editorial team and our partners to promote a partner’s work or perspective on a particular issue. It gives actors across the global development sector — including nongovernmental organizations, private sector stakeholders, aid agencies and government institutions — the opportunity to go beyond traditional advertising and tell their stories in an impactful way. If you'd like to learn more about how you can shine a spotlight on a particular issue with Devex, please email advertising@devex.com. We look forward to hearing from you.